Misplaced Pages

Canagliflozin/metformin, sold under the brand name Vokanamet among others, is a fixed-dose combination anti-diabetic medication used for the treatment of type 2 diabetes. It is used in combination with diet and exercise. It is taken by mouth.

The most common side effects include hypoglycemia (low blood glucose levels) when used in combination with insulin or a sulphonylurea and vulvovaginal candidiasis (thrush, a fungal infection of the female genital area caused by Candida).

Canagliflozin/metformin was approved for medical use in the European Union in April 2014, and for use in the United States in August 2014.

Medical uses

Canagliflozin/metformin is indicated in adults aged 18 years of age and older with type 2 diabetes as an adjunct to diet and exercise to improve glycemic control.

Adverse effects

To lessen the risk of developing ketoacidosis (a serious condition in which the body produces high levels of blood acids called ketones) after surgery, the FDA approved changes to the prescribing information for SGLT2 inhibitor diabetes medicines to recommend they be stopped temporarily before scheduled surgery. Canagliflozin, dapagliflozin, and empagliflozin should each be stopped at least three days before, and ertugliflozin should be stopped at least four days before scheduled surgery.

Symptoms of ketoacidosis include nausea, vomiting, abdominal pain, tiredness, and trouble breathing.

References

1. ^ "Vokanamet 50 mg/850 mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). 13 February 2020. Archived from the original on 3 March 2020. Retrieved 2 March 2020.
2. ^ "Invokamet- canagliflozin and metformin hydrochloride tablet, film coated Invokamet XR- canagliflozin and metformin hydrochloride tablet, film coated, extended release". DailyMed. 5 February 2020. Archived from the original on 7 June 2020. Retrieved 2 March 2020.
3. ^ "Vokanamet EPAR". European Medicines Agency (EMA). 18 February 2020. Archived from the original on 3 March 2020. Retrieved 2 March 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
4. "Drug Approval Package: Invokamet (canagliflozin and metformin hydrochloride) Tablets NDA #204353". U.S. Food and Drug Administration (FDA). 4 September 2014. Archived from the original on 3 March 2020. Retrieved 2 March 2020.
5. ^ "FDA revises labels of SGLT2 inhibitors for diabetes to include warning". U.S. Food and Drug Administration (FDA). 19 March 2020. Archived from the original on 7 June 2020. Retrieved 6 June 2020. This article incorporates text from this source, which is in the public domain.

Further reading

• Davidson JA, Sloan L (January 2017). "Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview". Adv Ther. 34 (1): 41–59. doi:10.1007/s12325-016-0434-2. PMC 5216068. PMID 27854055.

• Medicine

This drug article relating to the gastrointestinal system is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Biguanides
• Combination diabetes drugs
• Fluoroarenes
• Glucosides
• Guanidines
• SGLT2 inhibitors
• Thiophenes
• Gastrointestinal system drug stubs